Gold Falls Over 1%; American Outdoor Brands Shares Jump After Q1 Results
U.S. stocks fell as August jobs beat estimates; oil, gold and silver declined. Immuron, Quanex and AOUT surged, while GWRE, LULU and PATH dropped.
Stocks · News reference
Immuron Announces Publication Of Data From Its Phase 2 Clinical Trial Of Once-Daily Oral Travelan In 'Scientific Reports'; Statistically Significant 50% Reduction In ETEC Challenge-Related Adverse Events Versus Placebo
Immuron Limited ((ASX: IMC, NASDAQ:IMRN) today announced that data from its Phase 2 clinical trial of once-daily oral Travelan® has been published in the Nature Journal, Scientific Reports.A copy of the publication can
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Dow Falls Over 100 Points; US Economy Adds 162,000 Jobs In August
U.S. stocks mixed as Dow and S&P fell despite strong August job gains; tech rose, energy slid, and oil, gold and silver declined.
Immuron Stock Surges Friday: What's Driving the Action?
Immuron shares are surging Friday after it announced an exclusive deal with Calmino group AB to launch PROIBS gut health product in the U.S.